ImpediMed Limited (ASX:IPD)

Market Cap	95.35M
Revenue (ttm)	11.54M
Net Income (ttm)	-21.22M
Shares Out	2.03B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,297,896
Average Volume	3,473,916
Open	0.0470
Previous Close	0.0470
Day's Range	0.0450 - 0.0470
52-Week Range	0.0260 - 0.0680
Beta	2.35
RSI	55.35
Earnings Date	Jul 31, 2025

About ImpediMed

ImpediMed Limited, a medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema and deliver snapshot of fluid status and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-car body composition analysis; and HF-Dex analysis for point-or care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to anal...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 83
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IPD

Financial Performance

In 2024, ImpediMed's revenue was 10.32 million, a decrease of -9.04% compared to the previous year's 11.34 million. Losses were -19.79 million, -3.56% less than in 2023.